Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$25.84 -1.64%

-$0.38 today

Market cap
$1.80B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 0.57M

Average 0.71M

ZYME Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Zymeworks Inc.NASDAQ: ZYME

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares declines year over year

Q3 FY2026 weighted avg shares of 71.61M shares fell 5.5% year over year, behind the -2.5% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of -2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
71.61M-1.9% QoQ
Last fiscal yearDec 2025
75.34M-0.7% YoY
LTMSep 2026
73.65M-2.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.5%——
1 year-0.7%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
75.34M USD
Year-over-year change
-0.7%
4-year CAGR
+9.6%

Weighted Avg Shares vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 weighted avg shares of 73.65M shares is the 7th highest of the 11 companies compared; the peer median is 84.46M shares.
  • Its year-over-year change of -2.5% is the 10th highest of 11, against a peer median of +7.1%.
  • Over three fiscal years its annual growth of +4.9% compares with a peer median of +11.0%.
ZYME Competitors Peer median
Weighted Avg Shares for ZYME and competitors
Company Period LTM YoY 3-year CAGR
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.3%+28.0%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CGENCompugen Ltd.LTM Mar 202693.98M +4.2%+2.6%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
ZYMEZymeworks Inc.LTM Sep 202673.65M -2.5%+4.9%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
CBIOCrescent Biopharma, Inc.LTM Mar 202617.74M -57.8%-41.7%
Peer median (excluding ZYME) 84.46M+7.1%+11.0%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue26.68M412.48M76.01M76.3M105.97M
Cost of Revenue00142.99M00
Gross Profit26.68M412.48M(66.98M)76.3M105.97M
Gross Margin100.0%100.0%-88.1%100.0%100.0%
Research & Development199.75M208.6M143.62M134.62M137M
Selling, General & Admin42.6M73.4M70.4M61.5M61.5M
Operating Expenses242.31M281.95M71.08M213.41M198.5M
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
EBITDA(206.09M)142.49M(120.7M)(108.62M)(68.64M)
EBITDA Margin-772.4%34.5%-158.8%-142.4%-64.8%
Operating Income(215.63M)130.53M(138.05M)(137.11M)(92.54M)
Operating Margin-808.2%31.6%-181.6%-179.7%-87.3%
Interest Income1.97M3.6M19.71M19.94M13.35M
Interest Expense00000
Other Income / Expenses3.27M4.71M18.81M20.5M12.78M
Income Before Tax(212.36M)135.23M(119.24M)(116.61M)(79.75M)
Pre-Tax Margin-795.9%32.8%-156.9%-152.8%-75.3%
Income Tax Expense(516K)10.89M(568K)6.08M1.38M
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Net Margin-794.0%30.1%-156.1%-160.8%-76.6%
EPS (Basic)(4.06)1.91(1.72)(1.62)(1.08)
EPS (Diluted)(4.61)1.90(1.72)(1.62)(1.08)
Weighted Avg Shares52.13M65.19M68.86M75.85M75.34M
Weighted Avg Shares (Diluted)52.13M65.25M68.86M75.88M75.34M

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$25.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.